Antigenic and genetic characteristics of influenza B virus/Victoria lineage in Shanghai, 2018–2020
-
摘要:目的 分析2018 — 2020年上海市分离的B/Victoria系流感毒株与疫苗株的匹配性及基因变异情况。方法 利用血凝抑制实验,对142株B/Victoria系流感毒株进行了抗原性分析,并选取了63株开展了血凝素(HA)及神经氨酸酶(NA)基因序列分析。结果 2018 — 2020年上海市流行的B/Victoria系流感毒株主要属于V1A.3分支,少数属于V1A.1分支及未缺失的V1A分支;抗原性分析显示,26.76%的流行株是疫苗株B/Colorado/06/2017鸡胚株的低反应株,与疫苗株相比,V1A.3分支流行株在HA蛋白的120环、150环、160环及190螺旋等关键的抗原决定簇及受体结合关键部位发生了5个氨基酸位点改变。结论 2018 — 2020监测年度B/Victoria系流行株与世界卫生组织推荐的疫苗株组分B/Colorado/06/2017匹配性不佳,仍需密切监测流行株的谱系及变异情况,为疫苗株的筛选提供可靠的数据。Abstract:Objective To analyze the antigenic and genetic characteristics and variation of influenza B virus /Victoria lineage in Shanghai during 2018–2020.Methods Hemagglutinin inhibition test was performed to analyze the antigenicity of 142 strains of influenza B virus/Victoria lineage isolated in Shanghai from April 2018 to March 2020, in which 63 strains were used for hemagglutinin and neuraminidase gene sequencing and analysis.Results V1A.3 was predominant clade in influenza B virus B/Victoria lineage circulating in Shanghai. A few circulating strains belonged to clade V1A.1 and clade V1A without deletion. Only 26.76% of the circulating virus strains were antigenically similar to the B/Colorado/06/2017 vaccine strain. Five amino acids loci had mutation in the HA protein sequence of clade V1A.3 compared with the B/Colorado/06/2017 vaccine strain, involving 4 important epitopes and receptors, such as 120 loop, 150 loop, 160 loop and 190 helix.Conclusion The majority of influenza B virus /Victoria lineage circulating in Shanghai did not match well with the vaccine strain B/Colorado/06/2017 recommended by WHO. It is necessary to further strengthen the surveillance for influenza virus variation to provide reliable data for the screening of influenza vaccine strain.
-
Key words:
- Influenza virus B/Victoria lineage /
- Hemagglutimin /
- Neuraminidase /
- Antigenicity /
- Genetic characteristics /
- t /
- c
-
表 2 2018-2020年监测年度上海市分离的B/Victoria系流感病毒HA蛋白位点变异情况
Table 2. Mutation sites of amino acid of HA genes of influenza B virus/Victoria lineage isolated in Shanghai, 2018–2020
分支 位点 B/Colorado/06/2017 氨基酸变异情况 是否属于抗原决定簇 是否属于受体结合部位 是否属于糖基化位点 V1A.3 133 G G133R 120环 否 否 V1A.3 136 K K136E 120环 140环 否 V1A.3 164 D 缺失 160环 否 否 V1A.3 180 V V180I 否 否 否 V1A.3 197 T T197N/T197S 190螺旋 190螺旋 增加NETQ V1A.3 498 K K498R 否 否 否 V1A.3 184 G G184E 否 否 否 V1A.3 252 V V252M 否 否 否 V1A.3 279 R R279K 否 否 否 V1A 129 G G129D 120环 否 否 V1A 162 K 不缺失 160环 否 否 V1A 163 N 不缺失 160环 否 否 V1A 180 V V180I 否 否 否 V1A 197 T T197N/T197S 190螺旋 190螺旋 增加NETQ V1A 498 K K498R 否 否 否 -
[1] 周丽娟, 朱闻斐, 舒跃龙. 乙型流感病毒致病力相关分子标记研究进展[J/OL]. 病毒学报.(2020−06−17)[2020−08−10]. https://doi.org/1.013242/j.cnki.bingduxuebao.003757.Zhou LJ, Zhu WF, Shu YL. Advances in molecular markers related to the pathogenicity of influenza B viruses[J/OL]. Chi J Virol.(2020−06−17)[2020−08−10]. https://doi.org/1.013242/j.cnki.bingduxuebao.003757. [2] Nerome R, Hiromoto Y, Sugita S, et al. Evolutionary characteristics of influenza B virus since its first isolation in 1940: dynamic circulation of deletion and insertion mechanism[J]. Arch Virol, 1998, 143(8): 1569–1583. DOI: 10.1007/s007050050399. [3] Rota PA, Wallis TR, Harmon MW, et al. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983[J]. Virology, 1990, 175(1): 59–68. DOI: 10.1016/0042−6822(90)90186−u. [4] Tan Y, Guan WD, Lam TTY, et al. Differing epidemiological dynamics of influenza B virus lineages in Guangzhou, southern China, 2009–2010[J]. J Virol, 2013, 87(22): 12447–12456. DOI: 10.1128/JVI.01039−13. [5] 黄维娟, 谭敏菊, 蓝雨, 等. 2011-2012年度中国B型流感病毒病原学特征分析[J]. 病毒学报,2020,29(1):32–38. DOI: 10.13242/j.cnki.bingduxuebao.002349.Huang WJ, Tan MJ, Lan Y, et al. Virological characterization of influenza B virus in mainland China during 2011–2012[J]. Chin J Virol, 2020, 29(1): 32–38. DOI: 10.13242/j.cnki.bingduxuebao.002349. [6] 成艳辉, 王钊, 肖宁, 等. 2013-2014年中国B型流感病毒抗原性及基因特性分析[J]. 中华实验和临床病毒学杂志,2015,29(5):385–390. DOI:10.3760/cma.j.issn.1003−9279.2015.05.001.Cheng YH, Wang Z, Xiao N, et al. Antigenic and genetic characteristics of influenza B virus in the mainland of China 2013–2014[J]. Chin J Exp Clin Virol, 2015, 29(5): 385–390. DOI: 10.3760/cma.j.issn.1003−9279.2015.05.001. [7] Caini S, Huang QS, Ciblak MA, et al. Epidemiological and virological characteristics of influenza B: results of the Global Influenza B Study[J]. Influenza Other Respir Viruses, 2015, 9 Suppl 1: 3–12. DOI: 10.1111/irv.12319. [8] 冯录召, 彭质斌, 王大燕, 等. 中国流感疫苗预防接种技术指南(2018-2019)[J]. 中华预防医学杂志,2018,52(11):1101–1114. DOI:10.3760/cma.j.issn.0253−9624.2018.11.003.Feng LZ, Peng ZB, Wang DY, et al. Technical guidelines for seasonal influenza vaccination in China (2018–2019)[J]. Chin J Prev Med, 2018, 52(11): 1101–1114. DOI: 10.3760/cma.j.issn.0253−9624.2018.11.003. [9] 国家免疫规划技术工作组流感疫苗工作组. 中国流感疫苗预防接种技术指南(2019-2020)[J]. 中华预防医学杂志,2020,54(1):21–36. DOI:10.3760/cma.j.issn.0253−9624.2020.01.007.National Immunization Advisory Committee (NIAC) Technical Working Group (TWG), Influenza Vaccination TWG. Technical guidelines for seasonal influenza vaccination in China, 2019–2020[J]. Chin J Prev Med, 2020, 54(1): 21–36. DOI: 10.3760/cma.j.issn.0253−9624.2020.01.007. [10] Langat P, Raghwani J, Dudas G, et al. Conceptualization, data curation, et al. Genome-wide evolutionary dynamics of influenza B viruses on a global scale[J]. PLoS Pathog, 2017, 13(12): e1006749. DOI: 10.1371/journal.ppat.1006749. [11] 吴巨龙, 孙林, 张圣洋, 等. 山东省2017-2018年B型流感病毒药物敏感性检测及神经氨酸酶基因特征分析[J]. 中国人兽共患病学报,2019,35(3):229–233. DOI:10.3969/j.issn.1002−2694.2019.00.010.Wu JL, Sun L, Zhang SY, et al. Susceptibility to neuraminidase inhibitors and genetic characteristic of neuraminidase of influenza B viruses in Shandong province during 2017 to 2018[J]. Chin J Zoon, 2019, 35(3): 229–233. DOI: 10.3969/j.issn.1002−2694.2019.00.010. [12] Colman PM, Hoyne PA, Lawrence MC. Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase[J]. J Virol, 1993, 67(6): 2972–2980. DOI: 10.1128/JUI.67.6.2972−2980.1993. [13] Zhao BH, Qin SY, Teng Z, et al. Epidemiological study of influenza B in Shanghai during the 2009–2014 seasons: implications for influenza vaccination strategy[J]. Clin Microbiol Infect, 2015, 21(7): 694–700. DOI: 10.1016/j.cmi.2015.03.009. [14] Lei N, Wang HB, Zhang YS, et al. Molecular evolution of influenza B virus during 2011–2017 in Chaoyang, Beijing, suggesting the free influenza vaccine policy[J]. Sci Rep, 2019, 9: 2432. DOI: 10.1038/s41598−018−38105−1. [15] 赵丹, 孙睿, 苏志磊, 等. 2011-2018年青岛市B型流感病毒基因进化分析[J]. 中华微生物学和免疫学杂志,2019,39(6):410–416. DOI:10.3760/cma.j.issn.0254−5101.2019.06.002.Zhao D, Sun R, Su ZL, et al. Phylogenetic analysis of influenza B viruses in Qingdao from 2011 to 2018[J]. Chin J Microbiol Immunol, 2019, 39(6): 410–416. DOI: 10.3760/cma.j.issn.0254−5101.2019.06.002. [16] McCullers JA, Wang GC, He SQ, et al. Reassortment and insertion-deletion are strategies for the evolution of influenza B viruses in nature[J]. J Virol, 1999, 73(9): 7343–7348. DOI: 10.1128/jvi.73.9.7343−7348.1999. [17] WHO. Recommended composition of influenza virus vaccines for use in the 2020–2021 northern hemisphere influenza season[EB/OL]. (2020−02−28)[2020−08−26]. https://www.whoaw.int/influenza/vaccines/virus/recommendations/2020-21_north/en/. [18] ,Hao L S (Dddding Y H 2012 ). Progress of precipitation research in north China. Prog Geogr,31 (5 ):593 –601 (in Chinese)